Cargando…
Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
PURPOSE: To investigate the safety of five types of antiglaucoma prostaglandin analog ophthalmic formulations, and to clarify their differences in accordance with contained additives (preservatives and surface-active agents). METHODS: The following five types of ophthalmic solutions and three types...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601024/ https://www.ncbi.nlm.nih.gov/pubmed/23515900 http://dx.doi.org/10.2147/OPTH.S40147 |
_version_ | 1782475705248907264 |
---|---|
author | Fukuda, Masamichi Shibata, Shinsuke Shibata, Naoko Hagihara, Kenta Yaguchi, Hiromoto Osada, Hiromi Takahashi, Nobuo Kubo, Eri Sasaki, Hiroshi |
author_facet | Fukuda, Masamichi Shibata, Shinsuke Shibata, Naoko Hagihara, Kenta Yaguchi, Hiromoto Osada, Hiromi Takahashi, Nobuo Kubo, Eri Sasaki, Hiroshi |
author_sort | Fukuda, Masamichi |
collection | PubMed |
description | PURPOSE: To investigate the safety of five types of antiglaucoma prostaglandin analog ophthalmic formulations, and to clarify their differences in accordance with contained additives (preservatives and surface-active agents). METHODS: The following five types of ophthalmic solutions and three types of additives were investigated: latanoprost (Xalatan(®); latanoprost), tafluprost (Tapros(®); tafluprost), bimatoprost (Lumigan(®); bimatoprost), travoprost (Travatan(®); travoprost), travoprost (Travatan Z(®); travoprost-Z), benzalkonium chloride (BAK), polyoxyethylene hardening castor oil 40 (HCO-40), and polysorbate 80 (P-80). These experimental solutions were exposed to the cultured cells of a rabbit-derived corneal cell line for a certain time, and the exposure time causing 50% cell damage (CD50), indicated by the ratio of viable cells to total cells was calculated (in vitro). In addition, corneal resistance (CR) was measured and CR ratio (post-treatment CR/pretreatment CR × 100) was calculated (in vivo). RESULTS: CD50 of each ophthalmic solution was the longest with tafluprost, followed by travoprost-Z, bimatoprost, travoprost, and latanoprost. CD50 of 0.005%, 0.01%, and 0.02% BAK was 14.5 minutes, 8.1 minutes, and 4.0 minutes, respectively. The number of viable cells decreased to 60%, 8 minutes after exposure with HCO-40, and 30 minutes after being exposed to P-80. The CR ratio was 81.0% with travoprost and 82.0% with latanoprost, indicating a significant posttreatment reduction of CR (P < 0.05). The CR ratio did not decrease after treatment with tafluprost, travoprost-Z, or bimatoprost. The CR ratio of 0.005%, 0.01%, and 0.02% BAK was 105.0%, 90.5%, and 68.7%, respectively, and that of HCO-40 and P-80 was 108.7% and 114.2%, respectively. CONCLUSION: BAK, HCO-40, and P-80 were thought to be involved in corneal injuries caused by each ophthalmic solution. Corneal injuries due to surface action were observed when using HCO-40 and P-80. When HCO-40 was combined with BAK, it induced micellar BAK and reduced corneal injuries by BAK. |
format | Online Article Text |
id | pubmed-3601024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-36010242013-03-19 Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations Fukuda, Masamichi Shibata, Shinsuke Shibata, Naoko Hagihara, Kenta Yaguchi, Hiromoto Osada, Hiromi Takahashi, Nobuo Kubo, Eri Sasaki, Hiroshi Clin Ophthalmol Original Research PURPOSE: To investigate the safety of five types of antiglaucoma prostaglandin analog ophthalmic formulations, and to clarify their differences in accordance with contained additives (preservatives and surface-active agents). METHODS: The following five types of ophthalmic solutions and three types of additives were investigated: latanoprost (Xalatan(®); latanoprost), tafluprost (Tapros(®); tafluprost), bimatoprost (Lumigan(®); bimatoprost), travoprost (Travatan(®); travoprost), travoprost (Travatan Z(®); travoprost-Z), benzalkonium chloride (BAK), polyoxyethylene hardening castor oil 40 (HCO-40), and polysorbate 80 (P-80). These experimental solutions were exposed to the cultured cells of a rabbit-derived corneal cell line for a certain time, and the exposure time causing 50% cell damage (CD50), indicated by the ratio of viable cells to total cells was calculated (in vitro). In addition, corneal resistance (CR) was measured and CR ratio (post-treatment CR/pretreatment CR × 100) was calculated (in vivo). RESULTS: CD50 of each ophthalmic solution was the longest with tafluprost, followed by travoprost-Z, bimatoprost, travoprost, and latanoprost. CD50 of 0.005%, 0.01%, and 0.02% BAK was 14.5 minutes, 8.1 minutes, and 4.0 minutes, respectively. The number of viable cells decreased to 60%, 8 minutes after exposure with HCO-40, and 30 minutes after being exposed to P-80. The CR ratio was 81.0% with travoprost and 82.0% with latanoprost, indicating a significant posttreatment reduction of CR (P < 0.05). The CR ratio did not decrease after treatment with tafluprost, travoprost-Z, or bimatoprost. The CR ratio of 0.005%, 0.01%, and 0.02% BAK was 105.0%, 90.5%, and 68.7%, respectively, and that of HCO-40 and P-80 was 108.7% and 114.2%, respectively. CONCLUSION: BAK, HCO-40, and P-80 were thought to be involved in corneal injuries caused by each ophthalmic solution. Corneal injuries due to surface action were observed when using HCO-40 and P-80. When HCO-40 was combined with BAK, it induced micellar BAK and reduced corneal injuries by BAK. Dove Medical Press 2013 2013-03-12 /pmc/articles/PMC3601024/ /pubmed/23515900 http://dx.doi.org/10.2147/OPTH.S40147 Text en © 2013 Fukuda et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Original Research Fukuda, Masamichi Shibata, Shinsuke Shibata, Naoko Hagihara, Kenta Yaguchi, Hiromoto Osada, Hiromi Takahashi, Nobuo Kubo, Eri Sasaki, Hiroshi Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations |
title | Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations |
title_full | Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations |
title_fullStr | Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations |
title_full_unstemmed | Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations |
title_short | Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations |
title_sort | safety comparison of additives in antiglaucoma prostaglandin (pg) analog ophthalmic formulations |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601024/ https://www.ncbi.nlm.nih.gov/pubmed/23515900 http://dx.doi.org/10.2147/OPTH.S40147 |
work_keys_str_mv | AT fukudamasamichi safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations AT shibatashinsuke safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations AT shibatanaoko safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations AT hagiharakenta safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations AT yaguchihiromoto safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations AT osadahiromi safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations AT takahashinobuo safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations AT kuboeri safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations AT sasakihiroshi safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations |